Multifunctional peptide-conjugated hybrid silica nanoparticles for pho-todynamic therapy and MRI

Theranostics

Volumn 2, Issue 9, 2012, Pages 889-904

  Benachour, Hamanou ^a,b   Sève, Aymeric ^c   Bastogne, Thierry ^a,b,d   Frochot, Céline ^b,c   Vanderesse, Régis ^a,b   Jasniewski, Jor Dane ^e   Miladi, Imen ^f,g   Billotey, Claire ^f,g,h   Tillement, Olivier ^f,g   Lux, François ^f,g   Barberi Heyob, Muriel ^a,b,i  

^a UNIVERSITÉ DE LORRAINE   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d INRIA   (France)

^e UNIVERSITÉ DE LORRAINE   (France)

^f UNIVERSITÉ LYON 1   (France)

^g University of Lyon   (France)

^h HOSPICES CIVILS DE LYON   (France)

ⁱ CENTRE ALEXIS VAUTRIN   (France)

Author keywords

Brain tumor; Functionalized theranostic nanoparticles; MRI; Neuropilin 1; Targeted PDT

Indexed keywords

CHLORINATED HYDROCARBON; GADOLINIUM; NANOPARTICLE; NEUROPILIN 1; POLYSILOXANE; SILICON; TETRAXETAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHELATION; CONCENTRATION (PARAMETERS); CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOTOXICITY TEST; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYDRODYNAMICS; HYDROPHILICITY; MALE; NANOENCAPSULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PROTEIN TARGETING; RAT; ZETA POTENTIAL;

EID: 84868693491     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4754     Document Type: Article

References (56)

1. Weishaupt KR, Gomer CJ, Dougherty TJ. Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res. 1976; 36: 2326-9.
2. Fingar VH. Vascular effects of photodynamic therapy. J Clin Laser Med Surg. 1996; 14:323-8.
3. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M et al. Photodynamic therapy. J Natl Cancer Inst. 1998; 90: 889-905.
4. Bonnett R. Photosensitizers of the porphyrin and phthalocyanine series for photodynamic therapy. Chem Soc Rev. 1995; 24: 19-33.
5. McCaughan JS Jr. Photodynamic therapy: a review. Drugs Aging. 1999; 15: 49-68.
6. Del Governatore M, Hamblin MR, Shea CR, Rizvi I, Molpus KG, Tanabe KK et al. Experimental photoimmunotherapy of hepatic metastases of colorectal cancer with a 17.1A chlorin(e6) immunoconjugate. Cancer Res. 2000; 60: 4200-5.
7. Chaloin L, Bigey P, Loup C, Marin M, Galeotti N, Piechaczyk M et al. Improvement of porphyrin cellular delivery and activity by conjugation to a carrier peptide. Bioconjug Chem. 2001; 12: 691-700.
8. Sharman WM, van Lier JE, Allen CM. Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Deliv Rev. 2004; 56: 53-76.
9. Tang W, Xu H, Kopelman R, Philbert MA. Photodynamic characteriza-tion and in vitro application of methylene blue-containing nanoparticle platforms. Photochem Photobiol. 2005; 81: 242-9.
10. Konan YN, Berton M, Gurny R, Allémann E. Enhanced photodynamic activity of meso-tetra(4-hydroxyphenyl)porphyrin by incorporation into sub-200 nm nanoparticles. Eur J Pharm Sci. 2003; 18: 241-9.
11. Qin M, Hah HJ, Kim G, Nie G, Lee YE, Kopelman R. Methylene blue covalently loaded polyacrylamide nanoparticles for enhanced tu-mor-targeted photodynamic therapy. Photochem Photobiol Sci. 2011; 10: 832-41.
12. Tozer GM, Bicknell R. Therapeutic targeting of the tumor vasculature. Semin Radiat Oncol. 2004; 14: 222-32.
13. Chen B, Pogue BW, Luna JM, Hardman RL, Hoopes PJ, Hasan T. Tumor vascular permeabilization by vascular-targeting photosensitization: ef-fects, mechanism, and therapeutic implications. Clin Cancer Res. 2006; 12: 917-23.
14. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1: 27-31.
15. Ichikawa K, Hikita T, Maeda N, Yonezawa S, Takeuchi Y, Asai T et al. Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels. Biochim Biophys Acta. 2005; 1669: 69-74.
16. Fingar VH, Taber SW, Haydon PS, Harrison LT, Kempf SJ, Wieman TJ. Vascular damage after photodynamic therapy of solid tumors: a view and comparison of effect in pre-clinical and clinical models at the Uni-versity of Louisville. In Vivo. 2000; 14: 93-100.
17. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permea-bility and retention effect for tumor targeting. Drug Discov Today. 2006; 11: 812-8.
18. Starzec A, Ladam P, Vassy R, Badache S, Bouchemal N, Navaza A et al. Structure-function analysis of the antiangiogenic ATWLPPR peptide in-hibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex. Peptides. 2007; 28: 2397-402.
19. Tirand L, Frochot C, Vanderesse R, Thomas N, Trinquet E, Pinel S et al. A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photody-namic activity in human endothelial cells. J Control Release. 2006; 111: 153-64.
20. Thomas N, Bechet D, Becuwe P, Tirand L, Vanderesse R, Frochot C et al. Peptide-conjugated chlorin-type photosensitizer binds neuropilin-1 in vitro and in vivo. J Photochem Photobiol B. 2009; 96: 101-8.
21. Thomas N, Tirand L, Chatelut E, Plénat F, Frochot C, Dodeller M et al. Tissue distribution and pharmacokinetics of an ATWLPPR-conjugated chlorin-type photosensitizer targeting neuropilin-1 in glioma-bearing nude mice. Photochem Photobiol Sci. 2008; 7: 433-41.
22. Bechet D, Tirand L, Faivre B, Plénat F, Bonnet C, Bastogne T et al. Neu-ropilin-1 targeting photosensitization-induced early stages of thrombosis via tissue factor release. Pharm Res. 2010; 27: 468-79.
23. Tirand L, Thomas N, Dodeller M, Dumas D, Frochot C, Maunit B et al. Metabolic profile of a peptide-conjugated chlorin-type photosensitizer targeting neuropilin-1: an in vivo and in vitro study. Drug Metab Dispos. 2007; 35: 806-13.
24. Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photodynamic therapy: an emerging paradigm. Adv Drug Deliv Rev. 2008; 60: 1627-37.
25. Kopelmana R, Koo YEL, Philbert M, Moffat BA, Reddy GR, McConville P et al. Multifunctional nanoparticle platforms for in vivo MRI en-hancement and photodynamic therapy of a rat brain cancer. Journal of Magnetism and Magnetic Materials. 2005; 293: 404-10
26. Reddy GR, Bhojani MS, McConville P, Moody J, Moffat BA, Hall DE et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res. 2006; 12: 6677-86.
27. Zhao Z, Han Y, Lin C, Hu D, Wang F, Chen X et al. Multifunctional core-shell upconverting nanoparticles for imaging and photodynamic therapy of liver cancer cells. Chem Asian J. 2012; 7: 830-7.
28. Lee SJ, Park K, Oh YK, Kwon SH, Her S, Kim IS et al. Tumor specificity and therapeutic efficacy of photosensitizer-encapsulated glycol chi-tosan-based nanoparticles in tumor-bearing mice. Biomaterials. 2009; 30: 2929-39.
29. Bechet D, Couleaud P, Frochot C, Viriot ML, Guillemin F, Barberi-Heyob M. Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol. 2008; 26: 612-21.
30. Brevet D, Gary-Bobo M, Raehm L, Richeter S, Hocine O, Amro K, Loock B et al. Mannose-targeted mesoporous silica nanoparticles for photody-namic therapy. Chem Commun (Camb). 2009; (12): 1475-7.
31. Bridot JL, Faure AC, Laurent S, Rivière C, Billotey C, Hiba B et al. Hybrid gadolinium oxide nanoparticles: multimodal contrast agents for in vivo imaging. J Am Chem Soc. 2007; 129: 5076-84.
32. Faure AC, Dufort S, Josserand V, Perriat P, Coll JL, Roux S et al. Control of the in vivo biodistribution of hybrid nanoparticles with different poly(ethylene glycol) coatings. Small. 2009; 5: 2565-75.
33. Lux F, Mignot A, Mowat P, Louis C, Dufort S, Bernhard C et al. Ul-trasmall rigid particles as multimodal probes for medical applications. Angew Chem Int Ed Engl. 2011; 50: 12299-303.
34. Couleaud P, Bechet D, Vanderesse R, Barberi-Heyob M, Faure AC, Roux S et al. Functionalized silica-based nanoparticles for photodynamic therapy. Nanomedicine (Lond). 2011; 6: 995-1009.
35. Bazzi R, Flores-Gonzalez MA, Louis C, Lebbou K, Dujardin C, Brenier A, et al. Synthesis and uminescent properties of sub-5-nm lanthanide oxides nanoparticles. Journal of Luminescence. 2003; 102: 445-50
36. Bazzi R, Flores MA, Louis C, Lebbou K, Zhang W, Dujardin C et al. Synthesis and properties of europium-based phosphors on the nanome-ter scale: Eu2O3, Gd2O3:Eu, and Y2O3:Eu. J Colloid Interface Sci. 2004; 273: 191-7.
37. Louis C, Bazzi R, Marquette CA, Bridot JL, Roux S, Ledoux G et al. Nanosized hybrid particles with double luminescence for biological la-belling. Chem Mater. 2005; 17: 1673-82.
38. Thomas N, Pernot M, Vanderesse R, Becuwe P, Kamarulzaman E, Da Silva D et al. Photodynamic therapy targeting neuropilin-1: Interest of pseudopeptides with improved stability properties. Biochem Pharmacol. 2010; 80: 226-35.
39. Whitlock Jr HW, Hanauer R, Oester MY, Bower BK. Diimid reduction of porphyrins. J Am Chem Soc. 1969; 91: 7485-9.
40. Di Stasio B, Frochot C, Dumas D, Even P, Zwier J, Müller A et al. The 2-aminoglucosamide motif improves cellular uptake and photodynamic activity of tetraphenylporphyrin. Eur J Med Chem. 2005; 40: 1111-22.
41. Tanford C. Physical Chemistry of Macromolecules. Jonn Wiley and Sons: New York; 1961.
42. Kirstein SL, Atienza JM, Xi B, Zhu J, Yu N, Wang X et al. Live cell quality control and utility of real-time cell electronic sensing for assay devel-opment. Assay Drug Dev Technol. 2006; 4: 545-53.
43. Urcan E, Haertel U, Styllou M, Hickel R, Scherthan H, Reichl FX. Re-al-time xCELLigence impedance analysis of the cytotoxicity of dental composite components on human gingival fibroblasts. Dent Mater. 2010; 26: 51-8.
44. Schneider R, Schmitt F, Frochot C, Fort Y, Lourette N, Guillemin F et al. Design, synthesis, and biological evaluation of folic acid targeted tetra-phenylporphyrin as novel photosensitizers for selective photodynamic therapy. Bioorg Med Chem. 2005; 13: 2799-808.
45. Quereda JJ, Martínez-Alarcón L, Mendoça L, Majado MJ, Herre-ro-Medrano JM, Pallarés FJ et al. Validation of xCELLigence real-time cell analyzer to assess compatibility in xenotransplantation with pig-to-baboon model. Transplant Proc. 2010; 42: 3239-43.
46. Heng BC, Das GK, Zhao X, Ma LL, Tan TT, Ng KW et al. Comparative cytotoxicity evaluation of lanthanide nanomaterials on mouse and hu-man cell lines with metabolic and DNA-quantification assays. Biointer-phases. 2010; 5: FA88-97.
47. Soenen SJ, De Cuyper M. Assessing cytotoxicity of (iron oxide-based) nanoparticles: an overview of different methods exemplified with cati-onic magnetoliposomes. Contrast Media Mol Imaging. 2009; 4: 207-19.
48. Hanusová V, Králová V, Schröterová L, Trilecová L, Pakostová A, Skálová L. The effectiveness of oracin in enhancing the cytotoxicity of doxorubicin through the inhibition of doxorubicin deactivation in breast cancer MCF7 cells. Xenobiotica. 2010; 40: 681-90.
49. Soenen SJ, Rivera-Gil P, Montenegro JM, Parak WJ, De Smedt SC, Kevin Braeckmans. Cellular toxicity of inorganic nanoparticles: Common as-pects and guidelines for improved nanotoxicity evaluation. Nano Today. 2011; 6: 446-65
50. Mariani V, Ponti J, Giudetti G, Broggi F, Marmorato P, Gioria S et al. Online monitoring of cell metabolism to assess the toxicity of nanoparti-cles: the case of cobalt ferrite. Nanotoxicology. 2012; 6: 272-87.
51. Ross B, Rehemtulla A, Koo YEL, Reddy R, Kim G, Behrend C et al. Photonic and Magnetic Nanoexplorers for Biomedical Use: From Sub-cellular Imaging to Cancer Diagnostics and Therapy. Proc SPIE-Int Soc Optical Eng. 2004;:76-83.
52. Koo YE, Fan W, Hah H, Xu H, Orringer D, Ross B et al. Photonic ex-plorers based on multifunctional nanoplatforms for biosensing and photodynamic therapy. Appl Opt. 2007; 46: 1924-30.
53. Khemtong C, Kessinger CW, Gao J. Polymeric nanomedicine for cancer MR imaging and drug delivery. Chem Commun (Camb). 2009; (24): 3497-510.
54. Barreto JA, O'Malley W, Kubeil M, Graham B, Stephan H, Spiccia L. Nanomaterials: applications in cancer imaging and therapy. Adv Mater. 2011; 23: H18-40.
55. Liu T, Li X, Qian Y, Hu X, Liu S. Multifunctional pH-disintegrable mi-cellar nanoparticles of asymmetrically functionalized β-cyclodextrin-based star copolymer covalently conjugated with doxo-rubicin and DOTA-Gd moieties. Biomaterials. 2012; 33: 2521-31.
56. Ratzinger G, Agrawal P, Körner W, Lonkai J, Sanders HM, Terreno E et al. Surface modification of PLGA nanospheres with Gd-DTPA and Gd-DOTA for high-relaxivity MRI contrast agents. Biomaterials. 2010; 31: 8716-23.